The COVID-19 pandemic has affected design and conduct of all kinds of clinical trials, not only the specific areas of vaccines and therapeutics directly related to SARS-CoV-2 but also in other major therapeutic areas such as oncology/cancer treatment. This presentation provides three different perspectives on this subject:
- The non-profit perspective that is trying to understand the impact of COVID-19 on recruiting patients for cancer studies
- The pharma perspective on performing therapeutic and vaccine trials
- The lab perspective on designing and executing COVID-19 targeted therapeutic and vaccine trials
Download presentation to learn more.
Related Insights
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
